8-K filed Sep 15, 2026 at 08:44 ET
Summit Therapeutics presented updated overall survival (OS) data from the global Phase III HARMONi trial (ivonescimab + chemo in EGFR-mutated NSCLC) and detailed OS results from the China-based HARMONi-2 trial (ivonescimab monotherapy vs. pembrolizumab) at WCLC 2026. The HARMONi data showed a consistent OS benefit with a hazard ratio of 0.76 (nominal p=0.0151) in the global ITT population, with western patients now showing a similar HR of 0.76, reinforcing the drug's profile ahead of the November 14, 2026 PDUFA date. HARMONi-2 showed a statistically significant OS benefit for ivonescimab over pembrolizumab (HR 0.73, p=0.009), further strengthening the clinical case for the asset across multiple lung cancer settings.